Trastuzumab Deruxtecan in HER2-Low Breast Cancer
N Engl J Med
.
2022 Sep 22;387(12):1144.
doi: 10.1056/NEJMc2210368.
Authors
Hailey K Carroll
1
,
Michaela J Higgins
2
,
Seamus O'Reilly
3
Affiliations
1
Cork University Hospital, Cork, Ireland.
2
St Vincent's University Hospital, Dublin, Ireland.
3
Cork University Hospital, Cork, Ireland seamus.oreilly@hse.ie.
PMID:
36130005
DOI:
10.1056/NEJMc2210368
No abstract available
Publication types
Letter
Comment
MeSH terms
Breast Neoplasms* / drug therapy
Camptothecin / analogs & derivatives
Female
Humans
Immunoconjugates*
Trastuzumab / therapeutic use
Substances
Immunoconjugates
trastuzumab deruxtecan
Trastuzumab
Camptothecin